MariMed Inc (MRMD) Stock Analysis — March 2026
Executive Summary
MariMed Inc (OTC: MRMD) is a multi-state operator (mso) company currently priced at $0.08 per share with a market capitalization of $32.3M. The company generates trailing twelve-month revenue of $0 with a gross margin of 0.0% and year-over-year revenue growth of 0.00%. The stock trades on the OTC exchange in the United States market, and is positioned as a small-cap player within the cannabis sector.
Key Takeaways
MariMed Inc has a market cap of $32.3M, making it a small-cap cannabis company listed on the OTC.
Trailing twelve-month revenue is $0 with year-over-year growth of 0.0%. Declining revenue is a concern that warrants attention.
The company's gross margin stands at 0.0%. Low or negative margins raise questions about pricing power and cost structure.
MariMed Inc holds $0 in cash against $0 in debt, resulting in a net debt position of $0 and an estimated 0.0 months of cash runway.
The stock trades at a P/S ratio of 0.00x and EV/Revenue of 0.00x. Relatively low multiples could indicate an undervalued opportunity.
At $0.08, the stock trades at 10% of its 52-week range ($0.07 – $0.23). Trading near yearly lows could present value for contrarian investors.
The annual share dilution rate is 0.0%. Low dilution is a positive sign of disciplined capital management.
MariMed Inc Company Overview
MariMed Inc (OTC: MRMD) is a multi-state operator (mso) company currently trading at $0.08 per share with a market capitalization of $32.3M. The stock gained +8.14% in the most recent trading session on volume of 128.2K shares. MariMed Inc is headquartered in the United States and employs approximately 0 people. As a participant in the multi-state operator (mso) segment, the company operates within one of the most dynamic and rapidly evolving sectors of the North American economy.
On the revenue front, MariMed Inc generated $0 in trailing twelve-month (TTM) revenue, reflecting year-over-year growth of 0.0%. This growth rate is trailing the MSO sector average of 0.0%. MariMed Inc currently operates with a negative gross margin of 0.0%, meaning the company's cost of goods sold exceeds its revenue. This is a significant concern and suggests the business needs to either increase prices, reduce production costs, or achieve greater economies of scale. Revenue trends in the cannabis industry are closely watched by analysts, as the sector continues to navigate pricing compression, oversupply dynamics in certain markets, and the ongoing burden of IRS Section 280E, which prevents cannabis businesses from deducting ordinary business expenses at the federal level.
Financial Analysis
MariMed Inc generated $0 in trailing twelve-month revenue, reflecting year-over-year growth of 0.00%. The company's gross margin of 0.0% translates to approximately $0 in gross profit over the trailing twelve months. This margin profile places MariMed Inc in a negative margin position, indicating that the company's cost of goods sold exceeds its revenue — a significant concern for investors.
Revenue momentum is a critical metric for cannabis companies, as the industry continues to evolve through shifts in consumer demand, regulatory changes, and competitive dynamics. MariMed Inc's revenue decline of 0.00% is a notable concern that may be attributable to market headwinds, competitive pressure, pricing compression, or strategic transitions. Investors should closely monitor whether this trend stabilizes or accelerates in coming quarters. The cannabis industry's profitability dynamics are heavily influenced by IRS Section 280E, which prevents plant-touching operators from deducting ordinary business expenses for federal income tax purposes, effectively creating tax rates that can exceed 70% of gross profit.
Valuation Analysis
From a valuation perspective, MariMed Inc trades at a price-to-sales (P/S) ratio of 0.00x, which is below the sector median of 0.00x, which could indicate the stock is undervalued relative to peers or that the market has concerns about the company's growth trajectory. The enterprise value-to-revenue (EV/Revenue) multiple stands at 0.00x. Cannabis stock valuations have compressed significantly from their 2021 highs, and current multiples reflect a more mature market environment where investors demand clear paths to profitability. For context, the broader MSO sector contains 30 publicly traded companies tracked by CannaCap, and MariMed Inc's valuation should be considered within the context of its specific growth profile and competitive positioning.
At a price-to-sales ratio of 0.00x and an enterprise value-to-revenue multiple of 0.00x, MariMed Inc's valuation reflects the market's current assessment of the company's growth potential and risk profile. Enterprise value — calculated as market capitalization plus total debt minus cash — stands at approximately $32.3M, providing a more complete picture of the company's total valuation when accounting for balance sheet items. Investors should compare these multiples against both direct sector peers and historical ranges to determine whether MRMD is trading at a premium or discount.
Balance Sheet Deep Dive
MariMed Inc carries net debt of $0, with $0 in total debt against $0 in cash and equivalents. At the current pace, the company has an estimated 0.0 months of cash remaining, making capital management a critical near-term priority. Access to capital remains a persistent challenge for cannabis companies, particularly plant-touching operators that are excluded from traditional banking services and institutional lending. Many cannabis companies have turned to sale-leaseback transactions, private placements, and at-the-market (ATM) equity offerings to fund operations. MariMed Inc's balance sheet should be evaluated with these industry-specific constraints in mind.
MariMed Inc maintains a net cash position of $0, which represents a meaningful financial cushion. With $0 in cash and equivalents against $0 in total debt, the company has an estimated 0 months of operating runway at the current rate of cash consumption. This runway provides management with flexibility to pursue organic growth initiatives, evaluate strategic M&A opportunities, and navigate the capital-constrained cannabis industry without immediate pressure to raise dilutive equity capital.
The company's annual share dilution rate of 0.0% is relatively low, indicating disciplined capital management and reduced reliance on dilutive equity financing. Low dilution is a positive signal that the company is capable of funding operations through internal cash flows or non-dilutive sources. With 390.0M shares currently outstanding, any additional equity issuance directly impacts per-share metrics including earnings per share, book value per share, and ownership percentage.
Multi-State Operator (MSO) Sector Context
Within the Multi-State Operator (MSO) sector, MariMed Inc ranks #15 out of 30 companies by market capitalization, commanding a 0.4% share of the sector's total market cap of $7.30B. Multi-State Operators are vertically integrated cannabis companies that cultivate, process, and sell cannabis products across multiple U.S. states. MSOs typically hold licenses in several state-legal markets and operate dispensary retail chains alongside cultivation and manufacturing facilities. The largest company in the sector by market cap is Curaleaf Holdings (CURLF) at $1.80B, followed by Green Thumb Industries (GTBIF) at $1.54B.
By revenue, MariMed Inc ranks #1 in its sector with $0 in trailing twelve-month sales. The sector's top revenue generator is MariMed Inc at $0. MariMed Inc's gross margin of 0.0% compares to a sector average of 0.0%, placing it below the peer group midpoint. Revenue growth of 0.0% year-over-year reflects challenges that may include market headwinds, competitive pressure, or strategic transitions.
What distinguishes MariMed Inc within the Multi-State Operator (MSO) space includes the highest revenue generator among its peers; minimal share dilution at just 0.0% annually. These characteristics help define the company's competitive positioning and investment thesis relative to the 29 other MSO companies tracked by CannaCap. Investors comparing cannabis stocks within this sector should consider not just valuation multiples, but also balance sheet strength, management execution, and geographic or product diversification.
Historical Price Performance
MariMed Inc (MRMD) currently trades at $0.08, which places the stock at approximately 10% of its 52-week trading range. Over the past twelve months, MRMD has traded as high as $0.23 and as low as $0.07, representing a 243.3% spread between the yearly high and low. The current price sits 64.0% below the 52-week high and 23.7% above the 52-week low. This range provides important context for understanding the stock's recent volatility and where current levels fall within the broader price history.
In the most recent trading session, MRMD rose +8.14% from a previous close of $0.08 to $0.08, on volume of 128.2K shares. This positive session represents a significant single-day move that may have been driven by company-specific news, sector-wide sentiment, or broader market dynamics. The stock has 390,000,000 shares outstanding, giving it a fully diluted market capitalization that investors should factor into their analysis alongside the current $32.3M market cap figure.
Cannabis stocks have historically exhibited significant price volatility driven by regulatory developments, earnings surprises, and shifts in market sentiment toward the sector. MRMD is trading in the lower portion of its 52-week range, which could represent a value opportunity for contrarian investors, or may reflect deteriorating fundamentals that warrant caution. Historical price levels should be considered alongside fundamental data — including revenue trends, margin improvement, and balance sheet health — to form a complete investment thesis.
Investment Thesis
A balanced framework for evaluating MariMed Inc (MRMD) as a potential investment, considering both the upside catalysts and downside risks based on the company's current financial data and industry positioning.
Revenue stabilization and potential for operational improvements could reignite top-line growth. With TTM revenue of $0, even modest gains in market share or pricing power could meaningfully impact the company's financial trajectory and investor sentiment toward MRMD.
Potential for margin recovery as the cannabis market matures and pricing stabilizes. Regulatory reform — particularly the rescheduling of cannabis and elimination of Section 280E tax burdens — could dramatically improve the gross margin profile for MariMed Inc and the broader industry.
Federal cannabis reform — including potential rescheduling, banking access via the SAFE Banking Act, or eventual descheduling — would be a transformative catalyst for MariMed Inc and the entire cannabis sector. Any legislative progress could unlock institutional capital flows, improve banking access, and eliminate the Section 280E tax burden that suppresses profitability industry-wide.
Intensifying competition from both legal operators and the persistent illicit market could pressure MariMed Inc's revenue growth and margins. The cannabis industry remains highly fragmented, and market share gains are becoming increasingly difficult as more states award licenses and new competitors enter the market.
Cannabis companies continue to face restricted access to traditional banking, institutional capital, and federal bankruptcy protections. These structural disadvantages increase the cost of capital and limit MariMed Inc's financial flexibility compared to companies in federally legal industries, creating an uneven competitive landscape.
Regulatory uncertainty remains the single largest risk for MariMed Inc and all cannabis investments. Federal prohibition in the United States creates ongoing challenges including Section 280E tax burdens, limited interstate commerce, and the risk of enforcement actions. State-level regulatory changes, licensing moratoriums, and social equity requirements add additional layers of unpredictability that can materially impact the company's operations and growth plans.
Risk Factors
Key risks that investors should consider before investing in MariMed Inc (MRMD). This is not an exhaustive list, and investors should conduct their own due diligence.
Regulatory & Legal Risk
Cannabis remains a Schedule I controlled substance under federal law, creating fundamental legal uncertainty for MariMed Inc and all plant-touching cannabis operators. Changes in federal enforcement policy, state regulatory frameworks, or local ordinances could materially impact the company's operations, licensing, and financial performance. The evolving patchwork of state regulations creates compliance complexity and limits the ability to operate across state lines.
Balance Sheet & Liquidity Risk
With $0 in cash against $0 in total debt and an estimated 0 months of cash runway, MariMed Inc faces potential liquidity constraints. The company may need to secure additional financing through equity raises (which dilute shareholders), debt issuance (which increases financial risk), or asset sales (which may reduce operational capacity). Cannabis companies' limited access to traditional banking further constrains available financing options.
Section 280E Tax Burden
Under IRS Section 280E, cannabis businesses are prohibited from deducting ordinary business expenses for federal income tax purposes. This effectively results in tax rates that can exceed 70% of gross profit for plant-touching operators, significantly reducing cash flow available for reinvestment and debt service. While potential rescheduling could eliminate this burden, the timeline and outcome remain uncertain, and MariMed Inc's profitability metrics should be evaluated with this tax overhang in mind.
Market & Competition Risk
The cannabis industry faces pricing pressure from oversupply in mature markets, competition from the illicit market (which avoids regulatory costs and taxation), and evolving consumer preferences. MariMed Inc competes for market share against both established operators and well-funded new entrants. Price compression in key markets has squeezed margins across the industry, and any worsening of these trends could materially impact the company's revenue and profitability outlook.
Frequently Asked Questions
Common questions about MariMed Inc (MRMD) stock, answered with real-time data from Cannabismarketcap.
What is MariMed Inc's (MRMD) stock price today?
MariMed Inc (MRMD) stock is currently trading at $0.08 per share on the OTC exchange. This represents a daily gain of +8.14% ($0.01) from the previous closing price of $0.08. Over the past 52 weeks, MRMD has traded between a low of $0.07 and a high of $0.23, placing the current price at approximately -64% from its annual high. The stock has a market capitalization of $32.3M, making it a notable cannabis companies tracked by Cannabismarketcap. MariMed Inc operates in the MSO sector, serving the broader cannabis industry.
What is MariMed Inc's market capitalization?
MariMed Inc (MRMD) has a current market capitalization of $32.3M, calculated by multiplying its 390.0M shares outstanding by the current stock price of $0.08. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places MariMed Inc among the small-cap cannabis companies tracked on Cannabismarketcap. For context, the enterprise value (market cap plus debt minus cash) stands at $32.3M, which accounts for the company's balance sheet structure. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.
Is MariMed Inc profitable?
MariMed Inc (MRMD) currently reports a gross margin of 0.0%, which means the company loses 0.0 cents of every revenue dollar after direct costs of goods sold. Profitability is a critical factor in the cannabis industry, where many companies are still investing heavily in growth and regulatory compliance. Investors should review the full income statement, cash flow trends, and operating expense breakdown on Cannabismarketcap for a complete picture of MariMed Inc's financial health.
What are MariMed Inc's key financial metrics?
MariMed Inc (MRMD) reports several important financial metrics that investors track closely. The company has a market capitalization of $32.3M, trailing twelve month revenue of N/A, and a gross margin of 0.0%. On the balance sheet, MariMed Inc holds $0 in cash and equivalents against $0 in total debt, resulting in a debt-to-market-cap ratio of 0.00x. With 390.0M shares outstanding, investors should consider both the fundamental financial performance and share structure when evaluating MRMD.
What exchange is MRMD listed on?
MariMed Inc trades under the ticker symbol MRMD on the OTC exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts, though some brokers may charge additional fees for OTC-listed securities. The stock sees average daily trading volume of approximately 128.2K shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.
What sector is MariMed Inc in?
MariMed Inc is classified as a MSO company within the cannabis industry, meaning it operates as a multi-state operator with cannabis cultivation, processing, and retail operations across multiple US states. The MSO sector is a key segment of the cannabis market, and investors often compare companies within the same sector to identify relative outperformers. You can compare MRMD with other MSO stocks on Cannabismarketcap's sector page to see how it ranks on metrics like market cap, revenue, and margins.
What is MariMed Inc's gross margin?
MariMed Inc (MRMD) has a gross margin of 0.0%, which represents the percentage of revenue the company retains after paying for the direct cost of goods sold. Gross margin is a critical profitability indicator in the cannabis industry, where companies face unique cost pressures from regulatory compliance, testing requirements, and the tax burden of IRC Section 280E (which prevents cannabis companies from deducting standard business expenses). A negative gross margin like MariMed Inc's suggests the company is facing challenges in cost management or pricing.
How does MRMD compare to other cannabis stocks?
You can compare MariMed Inc (MRMD) side-by-side with any cannabis stock on Cannabismarketcap using the dedicated comparison tool. Key comparison metrics include market cap ($32.3M), trailing twelve month revenue (N/A), gross margin (0.0%), and price-to-sales ratio (N/A). MariMed Inc sits in the MSO sector, so the most relevant peer comparisons would be against other MSO companies, though cross-sector comparisons can also reveal interesting insights about relative valuation. Visit the rankings page to see where MRMD stands across all cannabis companies on metrics like revenue growth (0.00% YoY), cash position ($0), and employee count (N/A).
What is MRMD's 52-week trading range?
MariMed Inc (MRMD) has traded between a 52-week low of $0.07 and a 52-week high of $0.23, with the current price of $0.08 sitting approximately -64% from the annual high. This range represents a spread of $0.16 (243% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.
How does MariMed Inc's valuation compare to cannabis industry peers?
MariMed Inc (MRMD) is valued at a market capitalization of $32.3M, and an enterprise value of $32.3M. In the cannabis industry, valuations can vary significantly depending on sector (MSO, LP, Ancillary, etc.), growth rate, and path to profitability. MariMed Inc's current revenue trajectory of 0.00% YoY may result in a lower valuation relative to faster-growing peers. Investors can use the Cannabismarketcap rankings and comparison tools to benchmark MRMD against specific competitors on valuation multiples, growth rates, and profitability.
What is MariMed Inc's enterprise value?
MariMed Inc (MRMD) has an estimated enterprise value (EV) of $32.3M, which is calculated by taking the market capitalization of $32.3M, adding total debt of $0, and subtracting cash and equivalents of $0. Enterprise value is widely considered a more comprehensive measure of a company's total value than market cap alone because it accounts for the capital structure, including debt obligations and available liquidity. For cannabis companies in particular, where balance sheet health varies dramatically, enterprise value provides a more accurate picture of acquisition cost and relative valuation.
Is MariMed Inc stock overvalued or undervalued?
Determining whether MariMed Inc (MRMD) is overvalued or undervalued requires analyzing multiple valuation metrics in context. The stock is currently trading at $0.08, which is -64% from its 52-week high of $0.23, with a gross margin of 0.0%. Investors should consider the company's enterprise value of $32.3M, its cash position of $0, and the broader cannabis industry outlook when forming a valuation opinion. Cannabismarketcap provides all the data needed for a thorough analysis, but this information should not be considered investment advice.
What are the risks of investing in MariMed Inc?
Investing in MariMed Inc (MRMD) carries several risks that investors should carefully consider. First, the cannabis industry remains federally illegal in the United States, creating regulatory uncertainty that can impact stock prices, banking access, and tax obligations (notably IRC Section 280E). Second, MariMed Inc's balance sheet shows $0 in total debt against $0 in cash, which investors should monitor for dilution risk or liquidity concerns. Additionally, the stock has shown a 52-week range of $0.07 to $0.23, reflecting meaningful price volatility. As with all cannabis stocks, investors face risks from changing state regulations, competitive pressures, and the evolving legal landscape. This information is for educational purposes only and is not investment advice.
What is MariMed Inc's cash position and debt level?
MariMed Inc (MRMD) holds $0 in cash and equivalents on its balance sheet, set against $0 in total debt. This gives the company a net debt position of $0. Balance sheet strength is especially important in the cannabis industry, where companies often face limited access to traditional banking and capital markets. Investors should track these metrics over time on Cannabismarketcap to identify trends in cash consumption and debt management.
How many shares outstanding does MariMed Inc have?
MariMed Inc (MRMD) currently has 390.0M shares outstanding, which when multiplied by the current stock price of $0.08 gives the company its market capitalization of $32.3M. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.
Does MariMed Inc pay a dividend?
Most cannabis companies, including MariMed Inc (MRMD), do not currently pay dividends. The cannabis industry is still in a growth phase, and companies typically reinvest available capital into expanding operations, securing new licenses, building out retail and cultivation infrastructure, and navigating complex regulatory requirements. Additionally, the IRC Section 280E tax burden significantly reduces the free cash flow available for shareholder distributions. Investors in cannabis stocks should generally expect returns to come from capital appreciation rather than dividend income. If MariMed Inc initiates a dividend in the future, it would be reported in their SEC filings and reflected on Cannabismarketcap.
How can I research MariMed Inc stock before investing?
To research MariMed Inc (MRMD) before investing, start with the company overview on Cannabismarketcap, which provides current price ($0.08), market cap ($32.3M), and key financial metrics. Next, review the full financial statements page for quarterly revenue trends, margins, and balance sheet details. Check the analyst ratings page for Wall Street consensus and price targets, and the technical analysis page for chart patterns and momentum indicators. Compare MRMD against sector peers using the comparison tool to understand relative valuation. Review recent news coverage for regulatory developments or corporate events. Finally, read the investment analysis page for a comprehensive deep-dive. Cannabis investing carries unique risks including federal illegality, regulatory uncertainty, and limited banking access — always conduct thorough due diligence before making any investment decision.
What does MariMed Inc's market cap of $32.3M mean?
MariMed Inc's market capitalization of $32.3M represents the total market value of all its outstanding shares (390.0M shares multiplied by the current stock price of $0.08). Market cap is the primary measure investors use to classify companies by size: small-cap companies (under $100M) like MariMed Inc may offer higher growth potential but come with greater risk and lower liquidity. In the cannabis sector, market cap is especially important because it determines index weighting, institutional investment eligibility, and often correlates with the company's operational scale and geographic reach. MariMed Inc currently ranks # among cannabis stocks tracked on Cannabismarketcap.
What regulatory risks does MariMed Inc face?
MariMed Inc (MRMD), like all cannabis companies, faces significant regulatory risks that investors should understand. At the federal level, cannabis remains a Schedule I controlled substance in the United States, which restricts banking access, prevents standard business expense deductions under IRC Section 280E, and creates legal uncertainty. As a multi-state operator, MariMed Inc must comply with different regulatory frameworks in each state where it operates, and any changes to state licensing rules, tax rates, or market structure can directly impact revenue and profitability. Potential catalysts include federal rescheduling (which could ease 280E burdens), the SAFE Banking Act (which would improve banking access), and individual state legalization events. Conversely, regulatory setbacks such as license moratoriums, increased enforcement, or unfavorable tax policy changes pose downside risks. Investors should monitor legislative developments closely using Cannabismarketcap's news and legalization tracker.
More MRMD Research & Data
MRMD price, chart & key stats
Revenue, earnings & balance sheet
Quarterly earnings & EPS trends
Historical price & volume chart
Step-by-step buying guide
Side-by-side peer comparison
Detailed investment thesis & outlook
Disclaimer: The information presented on this page is for informational and educational purposes only and does not constitute investment advice, financial advice, trading advice, or any other kind of advice. Cannabismarketcap does not recommend that any security be bought, sold, or held by you. All investments involve risk, and the past performance of a security, industry, sector, market, financial product, trading strategy, or individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. Cannabis stocks carry additional risks including federal illegality, regulatory uncertainty, limited banking access, and high volatility. Always conduct your own research and consider consulting a qualified financial advisor before making investment decisions.